
Patient name

Name of epcoritamab treating physician

Treating physician's phone number (during office hours)

Treating physician's emergency care phone number (after office hours)

Next of kin emergency contact information

Dates of epcoritamab injections:

Step-up dose(s) _____

First full dose _____

This document has been approved by HSA as of 02-10-2024
SG-EDLBCL-240001 07-10-2024

abbvie

ABBVIE PTE LTD
9 North Buona Vista Drive #19-01
The Metropolis Tower One,
Singapore 138 588

Patient Card

Safety Information about Epkinly™ (epcoritamab)

Please carry this card with you at all times. Show it to any healthcare provider who sees you and when you go to any hospital.

Tell any healthcare provider who sees you that you are being treated with Epkinly™ (epcoritamab).

If you get any side effects following your treatment with epcoritamab, please talk to your doctor or nurse.

Be careful while driving, cycling, or using heavy or potentially dangerous machines. If you have any of the symptoms described on this card, you should avoid these activities.

Contact your healthcare provider to report any side effects.

This material was developed by AbbVie Inc. as part of the risk management plan for Epkinly. This material is not intended for promotional use. For distribution to the patient by healthcare professionals only.

Information for Patients

Epcoritamab may cause side effects which can be serious.

Call your doctor or get emergency help immediately if you have any of the following symptoms:

- Fever (38°C or higher)
- Dizziness or light-headedness
- Chills
- Fast heartbeat
- Difficulty/trouble breathing
- Headache
- Difficulty speaking or writing
- Drowsiness
- Confusion/disorientation
- Muscle weakness
- Seizures
- Memory loss

These are not all the possible side effects of epcoritamab. Tell your doctor if you have any symptom that bothers you or does not go away.

You should stay close to a healthcare facility for at least 24 hours following the administration of your first full dose.

Information for Healthcare Providers

- This patient is being treated with epcoritamab, a T-cell engaging bispecific antibody.
- Following treatment with epcoritamab, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) may occur, which may be serious if not treated promptly. CRS may occur several hours or days after epcoritamab administration, usually after the first full dose in Cycle 1. ICANS may occur several days or weeks after epcoritamab administration.
- **Refer to the Singapore package insert or contact the patient's treating physician immediately for further information about Epkinly™ (contact details overleaf).**